Title:
ALLEVIATING GRAFT VERSUS HOST DISEASE USING ENGINEERED INKT CELLS
Document Type and Number:
WIPO Patent Application WO/2024/040061
Kind Code:
A3
Abstract:
We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4-CD8-/+ subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.
Inventors:
YANG LILI (US)
LI YAN-RUIDE (US)
LI YAN-RUIDE (US)
Application Number:
PCT/US2023/072223
Publication Date:
April 25, 2024
Filing Date:
August 15, 2023
Export Citation:
Assignee:
UNIV CALIFORNIA (US)
International Classes:
A61K35/17; A61P37/06; C12N5/0783; C12N5/10; A61K35/15; A61P35/00
Attorney, Agent or Firm:
WOOD, William J. (US)
Download PDF:
Previous Patent: AP50 POLYMERASES AND USES THEREOF
Next Patent: ADAPTING TRANSMISSION SCHEDULES FOR A RADIO FREQUENCY (RF) ENVIRONMENT
Next Patent: ADAPTING TRANSMISSION SCHEDULES FOR A RADIO FREQUENCY (RF) ENVIRONMENT